SE9203753D0 - Expression system for producing apolipoprotein ai-m - Google Patents

Expression system for producing apolipoprotein ai-m

Info

Publication number
SE9203753D0
SE9203753D0 SE9203753A SE9203753A SE9203753D0 SE 9203753 D0 SE9203753 D0 SE 9203753D0 SE 9203753 A SE9203753 A SE 9203753A SE 9203753 A SE9203753 A SE 9203753A SE 9203753 D0 SE9203753 D0 SE 9203753D0
Authority
SE
Sweden
Prior art keywords
pct
apolipoprotein
expression system
sec
dna sequence
Prior art date
Application number
SE9203753A
Other languages
English (en)
Swedish (sv)
Inventor
T Sejlitz
M Lake
E Holmgren
L Abrahmsen
Aa Mikaelsson
C Kalderen
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9203753A priority Critical patent/SE9203753D0/xx
Publication of SE9203753D0 publication Critical patent/SE9203753D0/xx
Priority to IL10789693A priority patent/IL107896A/en
Priority to US08/448,606 priority patent/US5721114A/en
Priority to SK766-95A priority patent/SK76695A3/sk
Priority to FI952847A priority patent/FI952847A7/fi
Priority to PL93309292A priority patent/PL175955B1/pl
Priority to CA002150928A priority patent/CA2150928C/en
Priority to AU56637/94A priority patent/AU5663794A/en
Priority to PCT/SE1993/001061 priority patent/WO1994013819A1/en
Priority to DE69328442T priority patent/DE69328442T2/de
Priority to JP51405994A priority patent/JP3899121B2/ja
Priority to CZ19951487A priority patent/CZ290865B6/cs
Priority to DK94902173T priority patent/DK0677109T3/da
Priority to ES94902173T priority patent/ES2146646T3/es
Priority to AT94902173T priority patent/ATE191930T1/de
Priority to HU9501680A priority patent/HU220193B/hu
Priority to PT94902173T priority patent/PT677109E/pt
Priority to EP94902173A priority patent/EP0677109B1/en
Priority to MX9307855A priority patent/MX9307855A/es
Priority to ZA939266A priority patent/ZA939266B/xx
Priority to NO19952297A priority patent/NO319497B1/no
Priority to GR20000401651T priority patent/GR3033966T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9203753A 1992-12-11 1992-12-11 Expression system for producing apolipoprotein ai-m SE9203753D0 (sv)

Priority Applications (22)

Application Number Priority Date Filing Date Title
SE9203753A SE9203753D0 (sv) 1992-12-11 1992-12-11 Expression system for producing apolipoprotein ai-m
IL10789693A IL107896A (en) 1992-12-11 1993-12-06 Method for the production of apoliprotein ai-m and an expression vector enabling said production
EP94902173A EP0677109B1 (en) 1992-12-11 1993-12-09 Expression system for producing apolipoprotein ai-m
JP51405994A JP3899121B2 (ja) 1992-12-11 1993-12-09 アポリポ蛋白質ａｉ−ｍを製造するための発現方式
CZ19951487A CZ290865B6 (cs) 1992-12-11 1993-12-09 Expresní vektor poskytující extracelulární produkci apolipoproteinu AI-M (Milano)
FI952847A FI952847A7 (fi) 1992-12-11 1993-12-09 Ekspressiosysteemi apolipoproteiini AI-M:n tuottamiseksi
PL93309292A PL175955B1 (pl) 1992-12-11 1993-12-09 Wektor ekspresyjny, szczep E. coli transformowany tym wektorem oraz sposób produkcji apolipoproteiny Ai-M (Milano)
CA002150928A CA2150928C (en) 1992-12-11 1993-12-09 Expression system for producing apolipoprotein ai-m
AU56637/94A AU5663794A (en) 1992-12-11 1993-12-09 Expression system for producing apolipoprotein ai-m
PCT/SE1993/001061 WO1994013819A1 (en) 1992-12-11 1993-12-09 Expression system for producing apolipoprotein ai-m
DE69328442T DE69328442T2 (de) 1992-12-11 1993-12-09 Expressionssystem zur produktion von apolipoprotein ai-m
US08/448,606 US5721114A (en) 1992-12-11 1993-12-09 Expression system for producing apolipoprotein AI-M
SK766-95A SK76695A3 (en) 1992-12-11 1993-12-09 Expression system for producing apolipoprotein ai-m
DK94902173T DK0677109T3 (da) 1992-12-11 1993-12-09 Ekspressionssystem til fremstilling af apolipoprotein AI-M
ES94902173T ES2146646T3 (es) 1992-12-11 1993-12-09 Sistema de expresion que permite producir una apoliproteina ai-m.
AT94902173T ATE191930T1 (de) 1992-12-11 1993-12-09 Expressionssystem zur produktion von apolipoprotein ai-m
HU9501680A HU220193B (hu) 1992-12-11 1993-12-09 Expressziós rendszer apolipoprotein AI-M előállításához
PT94902173T PT677109E (pt) 1992-12-11 1993-12-09 Sistema de expressao para a producao de apoliproteina ai-m
ZA939266A ZA939266B (en) 1992-12-11 1993-12-10 Expression system for producing apolipoprotein AI-M
MX9307855A MX9307855A (es) 1992-12-11 1993-12-10 Sistema de expresion para producir apolipotroteina ai-m.
NO19952297A NO319497B1 (no) 1992-12-11 1995-06-09 Ekspresjonssystem for fremstilling av apolipoprotein AI-M
GR20000401651T GR3033966T3 (en) 1992-12-11 2000-07-17 Expression system for producing apolipoprotein ai-m.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9203753A SE9203753D0 (sv) 1992-12-11 1992-12-11 Expression system for producing apolipoprotein ai-m

Publications (1)

Publication Number Publication Date
SE9203753D0 true SE9203753D0 (sv) 1992-12-11

Family

ID=20388112

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9203753A SE9203753D0 (sv) 1992-12-11 1992-12-11 Expression system for producing apolipoprotein ai-m

Country Status (22)

Country Link
US (1) US5721114A (cs)
EP (1) EP0677109B1 (cs)
JP (1) JP3899121B2 (cs)
AT (1) ATE191930T1 (cs)
AU (1) AU5663794A (cs)
CA (1) CA2150928C (cs)
CZ (1) CZ290865B6 (cs)
DE (1) DE69328442T2 (cs)
DK (1) DK0677109T3 (cs)
ES (1) ES2146646T3 (cs)
FI (1) FI952847A7 (cs)
GR (1) GR3033966T3 (cs)
HU (1) HU220193B (cs)
IL (1) IL107896A (cs)
MX (1) MX9307855A (cs)
NO (1) NO319497B1 (cs)
PL (1) PL175955B1 (cs)
PT (1) PT677109E (cs)
SE (1) SE9203753D0 (cs)
SK (1) SK76695A3 (cs)
WO (1) WO1994013819A1 (cs)
ZA (1) ZA939266B (cs)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
ATE353957T1 (de) * 1995-11-09 2007-03-15 Us Gov Health & Human Serv Verwendung von lezithin-cholesterin- azetyltransferase für die behandlung von atherosklerose
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
CN1297932A (zh) * 1999-11-30 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人脂蛋白前体蛋白信号肽11和编码这种多肽的多核苷酸
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
EP1335938B1 (en) 2000-11-10 2010-09-22 F. Hoffmann-La Roche Ltd. Apolipoprotein construct
US7217785B2 (en) * 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
WO2003026492A2 (en) * 2001-09-28 2003-04-03 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
JP2005511713A (ja) * 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US20100204103A1 (en) * 2002-05-08 2010-08-12 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
PL374126A1 (en) * 2002-05-17 2005-10-03 Esperion Therapeutics, Inc. Methods and copositions for the treatment of ischemic reperfusion
AU2003239489A1 (en) 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
EP2402300B1 (en) 2003-01-23 2016-05-25 Esperion Therapeutics Inc. Hydroxyl compounds and compositions for cholesterol management and related uses
US20070065906A1 (en) * 2003-03-05 2007-03-22 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for producing heterologous protein in e. coli
EP1706131A4 (en) * 2003-12-15 2009-08-12 Univ California THE CELLULAR CHOLESTEROL EFFLUX STIMULATING HELICULAR SYNTHETIC PEPTIDES
US8926958B2 (en) * 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
CN1320119C (zh) * 2004-12-09 2007-06-06 复旦大学 人载脂蛋白ApoAⅠ在毕赤氏酵母胞内表达的方法
ATE533488T1 (de) 2005-08-22 2011-12-15 Melior Pharmaceuticals I Inc Verfahren und formulierungen zur modulierung von lyn-kinaseaktivität und behandlung assoziierter erkrankungen
CA2619943A1 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
DE102006004871A1 (de) 2006-02-02 2007-08-09 Wacker Chemie Ag Mikroorganismenstamm zur Produktion von rekombinanten Proteinen
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
CN101489577B (zh) 2006-06-01 2013-10-16 蒙特利尔心脏病学研究所 治疗心瓣膜病的方法和化合物
DE102006044841A1 (de) 2006-09-22 2008-04-03 Wacker Chemie Ag Signalpeptid zur Produktion von rekombinanten Proteinen
EP1903115B1 (de) 2006-09-22 2011-03-09 Wacker Chemie AG Verfahren zur fermentativen Herstellung von Antikörpern
DE102006050332A1 (de) 2006-10-25 2008-04-30 Wacker Chemie Ag DNS-Konstrukt und Verfahren zur fermentativen Herstellung von Fusionsproteinen
MX2009008135A (es) * 2007-01-31 2009-08-12 Nutrition 21 Inc Uso de histidinato de cromo para tratamiento de alteraciones cardiometabolicas.
JP2010518860A (ja) * 2007-02-20 2010-06-03 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド Ｌｙｎキナーゼの活性化剤の同定方法
ES2579229T3 (es) 2007-03-13 2016-08-08 Jds Therapeutics, Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
AU2008279242A1 (en) * 2007-07-23 2009-01-29 Melior Discovery, Inc. Methods of activating IRS-1 and AKT
JP5600065B2 (ja) * 2007-10-23 2014-10-01 ザ クリーブランド クリニック ファウンデーション オキシダント耐性アポリポ蛋白質ａ−１および類似ペプチド
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
CA3029724A1 (en) 2008-11-10 2010-05-14 Muthiah Manoharan Lipids and compositions for the delivery of therapeutics
EP2391343B1 (en) 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
MX343654B (es) 2009-02-16 2016-11-16 Cerenis Therapeutics Holding Sa Peptidos mimeticos de la apolipoproteina a-i.
EP2406376A1 (en) 2009-03-12 2012-01-18 Alnylam Pharmaceuticals, Inc. LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
CA3151387A1 (en) 2009-05-05 2010-11-11 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
NZ712719A (en) 2009-06-10 2017-03-31 Arbutus Biopharma Corp Improved lipid formulation
AP3574A (en) 2009-08-14 2016-02-08 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
DE102009053566B4 (de) * 2009-11-11 2014-08-14 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Mikroorganismen mit gesteigerter Sucrosemutaseaktivität
AU2010328336B2 (en) 2009-12-07 2017-03-02 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
EP2512449B1 (en) 2009-12-18 2019-08-07 The University of British Columbia Methods and compositions for delivery of nucleic acids
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
US20130158055A1 (en) 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
NZ605079A (en) 2010-06-03 2015-08-28 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012028522A1 (en) * 2010-08-30 2012-03-08 F. Hoffmann-La Roche Ag Alkaline feed
WO2012064824A1 (en) 2010-11-09 2012-05-18 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
JP5902197B2 (ja) 2011-01-11 2016-04-13 アルニラム・ファーマシューティカルズ・インコーポレーテッド Ｐｅｇ化脂質および薬剤送達のためのそれらの使用
DK2673296T3 (en) 2011-02-07 2019-02-18 Cerenis Therapeutics Holding Sa LIPOPROTEIN COMPLEXES AND PREPARATION AND APPLICATIONS THEREOF
JP6152346B2 (ja) 2011-03-01 2017-06-21 ジェーディーエス セラピューティックス、エルエルシーＪＤＳ Ｔｈｅｒａｐｅｕｔｉｃｓ，ＬＬＣ 糖尿病、低血糖、および関連障害の治療および予防のためのインスリンとクロムの組成物
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
MX359171B (es) 2011-12-12 2018-09-18 Melior Pharmaceuticals I Inc Tratamiento para diabetes tipo i y tipo ii.
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
US11865121B2 (en) 2016-02-11 2024-01-09 Nutrition21, LLC Chromium containing compositions for improving health and fitness
US10426817B2 (en) * 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
AU2018250795B2 (en) 2017-04-10 2022-02-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Treatment of adipocytes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
DE68917379T2 (de) * 1988-05-31 1994-12-01 Mitsubishi Chem Ind Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind.
DE3819463A1 (de) * 1988-06-08 1989-12-14 Behringwerke Ag Expressionsvektoren zur herstellung unfusionierter proteine in mikroorganismen
US5223407A (en) * 1988-08-31 1993-06-29 Allelix Inc. Excretion of heterologous proteins from e. coli
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
DE68916444T2 (de) * 1989-10-31 1994-11-03 Schering Corp., Kenilworth, N.J. Sekretorische e-coli-stämme.
DE4009268A1 (de) * 1990-03-22 1991-09-26 Consortium Elektrochem Ind Sekretion von hirudinderivaten
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein

Also Published As

Publication number Publication date
ZA939266B (en) 1994-08-08
DE69328442T2 (de) 2000-09-07
FI952847A0 (fi) 1995-06-09
DK0677109T3 (da) 2000-07-17
WO1994013819A1 (en) 1994-06-23
DE69328442D1 (de) 2000-05-25
CA2150928C (en) 2005-02-08
HU220193B (hu) 2001-11-28
NO952297D0 (no) 1995-06-09
GR3033966T3 (en) 2000-11-30
SK76695A3 (en) 1996-02-07
FI952847L (fi) 1995-06-09
FI952847A7 (fi) 1995-06-09
PL175955B1 (pl) 1999-03-31
IL107896A0 (en) 1994-04-12
MX9307855A (es) 1994-06-30
HU9501680D0 (en) 1995-08-28
PT677109E (pt) 2000-07-31
CA2150928A1 (en) 1994-06-23
EP0677109B1 (en) 2000-04-19
JP3899121B2 (ja) 2007-03-28
PL309292A1 (en) 1995-10-02
NO952297L (no) 1995-06-09
ES2146646T3 (es) 2000-08-16
US5721114A (en) 1998-02-24
CZ290865B6 (cs) 2002-11-13
HUT71697A (en) 1996-01-29
JPH08506723A (ja) 1996-07-23
NO319497B1 (no) 2005-08-22
IL107896A (en) 2004-06-01
EP0677109A1 (en) 1995-10-18
CZ148795A3 (en) 1996-01-17
ATE191930T1 (de) 2000-05-15
AU5663794A (en) 1994-07-04

Similar Documents

Publication Publication Date Title
SE9203753D0 (sv) Expression system for producing apolipoprotein ai-m
DE59814214D1 (de) Inhibitor-protein des wnt-signalwegs
FI954648A0 (fi) Proteiinien erottaminen
DK0770139T3 (da) En svamp, hvor areA-genet er blevet modificeret, samt et areA-gen fra aspergillus oryzae
DK0665882T3 (da) DNA-forbindelser omfattende sekvenser kodende for mannuronan C-5-epimerase
EP0763101A4 (en) NUCLEIC ACID SEQUENCES AND EXPRESSION SYSTEMS FOR HEPARINASE II AND HEPARINASE III FROM FLAVOBACTERIUM HEPARINUM
DE69738079D1 (de) Systeme zur massenherstellung von proteinen oder peptiden durch mikroorganismen der gattung humicola
ES2168459T3 (es) Secuencias amplificadoras derivadas del gen de la desmina, vectores que llevan estas secuencias y sus utilizaciones para la produccion de proteinas.
EP0546087A4 (cs)
ATE161050T1 (de) Gen für die glykoprotease aus pasteurella haemolytica
FI971100A0 (fi) Menetelmä yhdistelmä-DNA-proteiinien, plasmidien ja modifioitujen solujen tuottamiseksi
IT1247484B (it) Metodo per la preparazione di interleuchina 6
ATE150654T1 (de) Verfahren zur vernichtung von halogenkohlwasserstoffen
ATE202798T1 (de) D-aminosäure-oxidase kodierendes dns-fragment
AU656353B2 (en) New variants derived from interferons of type I, production process thereof and their applications
GB9603803D0 (en) Production of proteins, plasmids coding therefor and organisms containing such plasmids
ITMI930844A1 (it) Metodo per la codifica e decodifica differenziale e relativi circuiti
DE59306940D1 (de) Verfahren zur herstellung rekombinanter proteine in streptomyceten
SE9903341L (sv) Förfarande och system för kontroll
KR830005348A (ko) 인체 인터페론의 아미노산 서열을 가진 미생물학적으로 제조된 폴리펩타이드, 아미노산 서열, 유전정보가 함유된 미생물에 코딩으로 작용하는 dna 및 플라스미드와 이의 제조방법